A Prospective Study of Azilsartan Medoxomil in the Treatment of Patients with Essential Hypertension and Type 2 Diabetes in Asia

Table 3

Percentage of patients treated with CCBs, ACE/ARBs, and thiazides before baseline 215 reaching BP < 140/85 mm Hg using GEE (logistic regression model): FAS and LOCF.

Visit	Patients with trough BP < 140/85 mm Hg
	CCBs	ACE inhibitors/ARBs	Thiazides
	(N  = 112)	(N  = 202)	(N  = 30)
Week 6
N′	109	193	29
n (%)	63 (57.8)	123 (63.7)	23 (79.3)
Adjusted %^∗	58.8	57.3	72.9
99% CI	(45.36, 71.12)	(44.83, 68.92)	(45.97, 89.46)
95% CI	(48.60, 68.38)	(47.81, 66.30)	(52.83, 86.57)
Week 12
N′	109	193	29
n (%)	57 (52.3)	123 (63.7)	25 (86.2)
Adjusted %^∗	52.6	57.3	83.8
99% CI	(39.75, 65.08)	(44.73, 69.01)	(43.81, 97.18)
95% CI	(42.76, 62.21)	(47.73, 66.37)	(55.08, 95.64)

ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; CI, confidence interval; FAS, full analysis set; GEE, generalized estimated equation; LOCF, last observation carried forward. N' = number of patients with nonmissing values and used as denominator to calculate percentage. ^∗The GEE logistic regression model was adjusted for baseline SBP (systolic blood pressure), country, baseline hypertension treatment status, and visit. One patient from the treatment-naïve group was considered only in the overall analysis.